ADXN Live signaler | Maksimer profitt med Getagraph.com

Live Chart Being Loaded With Signals

Commentary (30 apr 2024 @ 22:00):

Stats
Dagens volum	63 362.00
Gjennomsnittsvolum	18 803.00
Markedsverdi	22.06M
EPS	$0 ( 2024-04-04 )
Neste inntjeningsdato	( $0 ) 2024-05-09
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.420
ATR14	$0.0990 (1.24%)

Volum Korrelasjon

Lang: -0.05 (neutral)

Kort: -0.85 (strong negative)

Signal:(46.243) Neutral

Addex Therapeutics Ltd Korrelasjon

10 Mest positive korrelasjoner
SVAC	0.974
CVGI	0.957
CYN	0.956
MESA	0.955
DARE	0.954
WISA	0.954
MCRB	0.952
UCTT	0.952
CFRX	0.952
CURI	0.952

10 Mest negative korrelasjoner
NETE	-0.974
LDHA	-0.965
VLAT	-0.964
HORI	-0.964
LGAC	-0.96
MSDAU	-0.96
ABGI	-0.96
HCNE	-0.96
HERAU	-0.959
CRZN	-0.959

Visste du det?

Korrelasjon er en statistisk måling som beskriver forholdet mellom to variabler. Den varierer fra -1 til 1, hvor -1 indikerer en perfekt negativ korrelasjon (hvor en variabel øker, går den andre ned), 1 indikerer en perfekt positiv korrelasjon (hvor en variabel øker, går den andre også opp), og 0 indikerer ingen korrelasjon (det er ingen forhold mellom variablene).

Korrelasjon kan brukes til å analysere forholdet mellom to variabler, ikke bare aksjer. Det er vanligvis brukt innen områder som finans, økonomi, psykologi, og mer.

Addex Therapeutics Ltd Korrelasjon - Valuta/Råvare

-0.03
( neutral )

0.47
( neutral )

0.00
( neutral )

0.12
( neutral )

0.21
( neutral )

Addex Therapeutics Ltd Økonomi

Annual	2023
Omsetning:	$1.61M
Bruttogevinst:	$-5.32M (-329.99 %)
EPS:	$-0.140

FY	2023
Omsetning:	$1.61M
Bruttogevinst:	$-5.32M (-329.99 %)
EPS:	$-0.140

FY	2022
Omsetning:	$1.42M
Bruttogevinst:	$-13.20M (-928.06 %)
EPS:	$-0.460

FY	2021
Omsetning:	$2.92M
Bruttogevinst:	$0.00 (0.00 %)
EPS:	$-2.70

Financial Reports:

No articles found.

Addex Therapeutics Ltd

Addex Therapeutics Ltd, a development-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule pharmaceutical products for central nervous system (CNS) disorders in Switzerland. The company focuses on the discovery of oral small molecule allosteric modulators of G-protein coupled receptors. Its lead programs include Dipraglurant for the treatment of Parkinson's disease levodopa-induced dyskinesia, and dystonia; ADX71149 for epilepsy and undisclosed CNS disorders; and GABAB PAM for addiction. It has license and collaboration agreement with Janssen Pharmaceuticals Inc.; Indivior PLC; and The CharcotMarieTooth Association. The company was formerly known as Addex Pharmaceuticals Ltd and changed its name to Addex Therapeutics Ltd in March 2012. Addex Therapeutics Ltd was founded in 2002 and is headquartered in Geneva, Switzerland.